For many older Americans, this is a bitter time of year with a deceptively sweet name: the "doughnut hole."
It's not a treat from the local bakery, but rather a coverage gap in the three-year-old Medicare Part D drug program. When Part D was first designed as a way to help elderly patients pay for their prescription drugs, the only way the federal government could afford it was to impose a yearly limit on what it would cover for each member. So once seniors consume drugs up to that threshold—it is $2,510 in 2008—they fall into the doughnut hole. They then have to pay fully out of pocket for their drugs until the end of the year, or until they're eligible for catastrophic coverage, whichever comes first.
The doughnut hole has been a source of angst ever since Part D began in 2004. Now we know why: One way seniors deal with being in the hole is to stop taking their drugs.
Only recently have pollsters been able to quantify the fallout of the doughnut hole. In August, the Henry J. Kaiser Family Foundation released results of a survey showing that in 2007, 26% of Part D beneficiaries—3.4 million people—reached the doughnut hole. Part D plans are offered and managed by private insurance companies, so the particulars differ among the 1,600 or so plans that are available. But on average, Part D patients who fell into the doughnut hole saw their monthly out-of-pocket costs double to $196.
Even more alarming was that the study found 15% of people with chronic illnesses stopped taking drugs during the time they were in the coverage gap. "High drug costs are a barrier, but this is the first time we're seeing it documented so plainly," says Tricia Neuman, vice-president at Kaiser Family Foundation, a Menlo Park (Calif.) health research organization. "This raises concerns about the consequences for people with serious chronic conditions."
So what is the purpose of the doughnut hole exactly? It was the only solution to a simple problem: The federal government, which is expected to spend between $395 billion and $534 billion on Part D benefits through 2013, didn't allocate a big enough budget to the program to subsidize an unlimited supply of drugs for every beneficiary. Some of the insurance companies that sell Part D plans offer options that cover drugs during the gap. But, says David Certner, legislative policy director for AARP, "those plans cost more and they only cover generic drugs."
Since seniors already have to pay premiums and co-pays on their Part D plans, many choose to risk falling into the hole rather than to pay more for the chance of staying out of it.
Larry Kay of Yukaipa, Calif., is having so much trouble affording the doughnut hole that he's thinking about coming out of retirement. Kay, a former quality-control inspector for a fencing company, hit the hole in May and is now paying $650 a month for drugs to treat his high cholesterol and the lung condition chronic obstructive pulmonary disease, or COPD. "One is $162, another is $226," he says, rattling the exact prices off the top of his head with the tone of both familiarity and annoyance. "They don't have generics."
Kay's pension of $1,198 per month (after taxes) leaves little left over for other essentials. So he has stopped taking his COPD inhaler in the morning, even though he's not supposed to skip doses. "If my doctor knew, he'd be very upset."
Health policy experts believe that the next Administration will be under pressure to address the doughnut hole, and both candidates have expressed some support for reforming the program. Senator Barack Obama (D-Ill.) endorses the idea of letting the government negotiate drug prices for Part D (it doesn't have the right to do so now). Senator John McCain (R-Ariz.) has said that higher-income beneficiaries should pay higher premiums for their Part D plans.